17/57
1.5 / 5 stars
All 57 Win/Lose results and 63 gray no-data contests shown below
GYRE Roast Me summary
GYRE THERAPEUTICS, INC. (GYRE). Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth No data.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth No data.
Trailing 1 year (4 quarters): 4 wins, 6 losses, 2 no dataLast fetched: 24 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/2 |
LoseGYRE / S&P -5.45% / 15.20% |
LoseGYRE / S&P 13.53% / 15.00% |
No dataGYRE / S&P / 50.40% |
| 2026-Q12/3 |
WinGYRE / S&P -1.27% / -4.33% |
WinGYRE / S&P 19.25% / 11.30% |
LoseGYRE / S&P -700.00% / 27.70% |
| 2025-Q41/3 |
LoseGYRE / S&P -5.36% / 2.65% |
WinGYRE / S&P 10.24% / 9.00% |
LoseGYRE / S&P -60.00% / 13.40% |
| 2025-Q31/2 |
LoseGYRE / S&P 1.50% / 8.12% |
WinGYRE / S&P 4.95% / 4.61% |
No dataGYRE / S&P / 13.45% |
| 2025-Q20/2 |
LoseGYRE / S&P -4.79% / 10.94% |
LoseGYRE / S&P -5.77% / 4.83% |
No dataGYRE / S&P / 10.63% |
| 2025-Q10/2 |
LoseGYRE / S&P -36.20% / -4.27% |
LoseGYRE / S&P -13.01% / 4.98% |
No dataGYRE / S&P / 10.57% |
| 2024-Q40/2 |
LoseGYRE / S&P -3.51% / 2.41% |
LoseGYRE / S&P -6.78% / 5.25% |
No dataGYRE / S&P / 6.15% |
| 2024-Q30/1 |
LoseGYRE / S&P 5.11% / 5.89% |
No dataGYRE / S&P / 5.89% |
No dataGYRE / S&P / 6.11% |
| 2024-Q20/1 |
LoseGYRE / S&P -31.75% / 4.28% |
No dataGYRE / S&P / 5.38% |
No dataGYRE / S&P / 5.12% |
| 2024-Q10/2 |
LoseGYRE / S&P -31.96% / 10.56% |
No dataGYRE / S&P / 5.71% |
LoseGYRE / S&P -371.15% / 5.59% |
| 2023-Q42/3 |
WinGYRE / S&P 256.81% / 11.69% |
WinGYRE / S&P 10.91% / 6.81% |
LoseGYRE / S&P -4800.00% / 7.78% |
| 2023-Q31/2 |
WinGYRE / S&P 37.14% / -3.27% |
No dataGYRE / S&P / 7.52% |
LoseGYRE / S&P -334.21% / -5.03% |
| 2023-Q21/1 |
WinGYRE / S&P 66.67% / 8.74% |
No dataGYRE / S&P / 9.50% |
No dataGYRE / S&P / -8.57% |
| 2023-Q10/1 |
LoseGYRE / S&P -35.99% / 7.50% |
No dataGYRE / S&P / 10.77% |
No dataGYRE / S&P / -15.69% |
| 2022-Q41/2 |
LoseGYRE / S&P 6.00% / 7.56% |
WinGYRE / S&P 1293.98% / 11.88% |
No dataGYRE / S&P / -17.99% |
| 2022-Q31/1 |
WinGYRE / S&P 6.85% / -4.88% |
No dataGYRE / S&P / 13.47% |
No dataGYRE / S&P / -1.41% |
| 2022-Q21/1 |
WinGYRE / S&P 169.70% / -16.10% |
No dataGYRE / S&P / 13.71% |
No dataGYRE / S&P / 11.04% |
| 2022-Q10/2 |
LoseGYRE / S&P -27.47% / -4.60% |
LoseGYRE / S&P 10.18% / 15.97% |
No dataGYRE / S&P / 42.23% |
| 2021-Q40/2 |
LoseGYRE / S&P -77.86% / 11.03% |
LoseGYRE / S&P -64.97% / 15.00% |
No dataGYRE / S&P / 96.40% |
| 2021-Q30/1 |
LoseGYRE / S&P -5.08% / 0.58% |
No dataGYRE / S&P / 10.77% |
No dataGYRE / S&P / 69.42% |
| 2021-Q20/1 |
LoseGYRE / S&P -14.09% / 8.55% |
No dataGYRE / S&P / 6.58% |
No dataGYRE / S&P / 51.81% |
| 2021-Q10/1 |
LoseGYRE / S&P -20.13% / 6.17% |
No dataGYRE / S&P / -1.06% |
No dataGYRE / S&P / 7.39% |
| 2020-Q41/1 |
WinGYRE / S&P 46.74% / 12.15% |
No dataGYRE / S&P / -3.72% |
No dataGYRE / S&P / -33.42% |
| 2020-Q30/1 |
LoseGYRE / S&P -26.75% / 8.93% |
No dataGYRE / S&P / -2.04% |
No dataGYRE / S&P / -27.10% |
| 2020-Q21/1 |
WinGYRE / S&P 34.32% / 20.54% |
No dataGYRE / S&P / -0.46% |
No dataGYRE / S&P / -27.11% |
| 2020-Q10/1 |
LoseGYRE / S&P -35.83% / -19.60% |
No dataGYRE / S&P / 3.47% |
No dataGYRE / S&P / -14.75% |
| 2019-Q41/1 |
WinGYRE / S&P 38.70% / 9.07% |
No dataGYRE / S&P / 5.36% |
No dataGYRE / S&P / 2.99% |
| 2019-Q30/1 |
LoseGYRE / S&P -33.38% / 1.70% |
No dataGYRE / S&P / 5.02% |
No dataGYRE / S&P / 0.21% |
| 2019-Q20/1 |
LoseGYRE / S&P -9.12% / 4.30% |
No dataGYRE / S&P / 6.64% |
No dataGYRE / S&P / 8.65% |
| 2019-Q10/1 |
LoseGYRE / S&P 2.79% / 13.65% |
No dataGYRE / S&P / 8.12% |
No dataGYRE / S&P / 14.29% |
| 2018-Q40/2 |
LoseGYRE / S&P -26.81% / -13.52% |
LoseGYRE / S&P -99.41% / 9.05% |
No dataGYRE / S&P / 18.23% |
| 2018-Q30/1 |
LoseGYRE / S&P -7.63% / 7.71% |
No dataGYRE / S&P / 10.21% |
No dataGYRE / S&P / 19.06% |
| 2018-Q20/1 |
LoseGYRE / S&P -54.77% / 3.43% |
No dataGYRE / S&P / 9.03% |
No dataGYRE / S&P / 14.46% |
| 2018-Q11/1 |
WinGYRE / S&P 89.15% / -0.76% |
No dataGYRE / S&P / 7.68% |
No dataGYRE / S&P / 12.46% |
| 2017-Q41/1 |
WinGYRE / S&P 169.57% / 6.64% |
No dataGYRE / S&P / 7.03% |
No dataGYRE / S&P / 13.82% |
| 2017-Q31/1 |
WinGYRE / S&P 8.82% / 4.48% |
No dataGYRE / S&P / 5.68% |
No dataGYRE / S&P / 17.57% |
| 2017-Q20/1 |
LoseGYRE / S&P -50.69% / 3.09% |
No dataGYRE / S&P / 4.83% |
No dataGYRE / S&P / 17.74% |
| 2017-Q10/1 |
LoseGYRE / S&P -3.28% / 6.07% |
No dataGYRE / S&P / 3.67% |
No dataGYRE / S&P / 13.32% |
| 2016-Q40/1 |
LoseGYRE / S&P -46.28% / 3.82% |
No dataGYRE / S&P / 2.09% |
No dataGYRE / S&P / 7.05% |
| 2016-Q30/1 |
LoseGYRE / S&P -20.39% / 3.85% |
No dataGYRE / S&P / 0.20% |
No dataGYRE / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | GYRE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -14.60% | 20.78% |
| Annualized return | -14.60% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | GYRE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -43.82% | 83.14% |
| Annualized return | -10.89% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | GYRE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -84.96% | 319.30% |
| Annualized return | -17.26% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-24.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |